CA-170

First-in-Class Suppressor of VISTA

(Oral, Small Molecule VISTA/PD-L1 Antagonist)

Immune cells and certain human cancers express a ligand on their cell surface referred to as Programmed Cell Death Ligand-1 (PD-L1) which binds to its cognate receptor, Programmed Cell Death Protein-1 (PD-1) present on the surface of the immune system’s T cells. Cell surface interactions between tumor cells and T cells through PD-L1/PD-1 molecules result in T cell inactivation and hence the inability to mount an effective immune response against the tumor. It has been previously shown that modulation of the PD-1 mediated inhibition of T cells by either anti-PD-1 antibodies or anti-PD-L1 antibodies can lead to T cell activation that result in the observed anti-tumor effects in the tumor tissues. Therapeutic monoclonal antibodies targeting the PD-1/PD-L1 interactions have now been approved by the FDA for the treatment of certain cancers, and multiple therapeutic monoclonal antibodies targeting PD-1 or PD-L1 are currently in development.

In addition to PD-1/PD-L1 immune regulators, there are several other checkpoint molecules that are involved in the modulation of immune responses to tumor cells1. One such regulator is V-domain Ig suppressor of T-cell activation (VISTA) that shares structural similarity with PD-L1 and is also a potent suppressor of T cell functions. The expression of VISTA is different from that of PD-L1, and appears to be limited to the hematopoietic compartment in tissues such as spleen, lymph nodes and blood as well as on the surface of myeloid hematopoietic cells within the tumor microenvironment. Recent animal studies have demonstrated that combined targeting/blockade of PD-1/PD-L1 interactions and VISTA result in improved anti-tumor responses in certain tumor models, highlighting their distinct and non-redundant functions in regulating the immune response to tumors2.

As part of the collaboration with Aurigene, in October 2015, Curis licensed a first-in-class oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA, both of which function as negative checkpoint regulators of immune activation. Preclinical ex vivo data demonstrate that CA-170 can induce effective proliferation and IFN-γ (Interferon-gamma) production -a cytokine that is produced by activated T cells and is a marker of T cell activation- by T cells that are specifically suppressed by PD-L1 or VISTA. In addition, CA-170 also appears to have anti-tumor effects similar to anti-PD-1 or anti-VISTA antibodies in multiple in vivo tumor models. In preclinical toxicology studies, CA-170 appeared safe when administered at multiple dose levels using a once daily oral dosing schedule.

For more information on current trials click here.

Posters and Presentations

1Le Mercier I, et al., Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators. Front Immunol. (2015) 6:418. https://doi.org/10.3389/fimmu.2015.00418

2Liu J, et al., Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc Natl Acad Sci U S A. 2015 May 26;112(21):6682-7. https://doi.org/10.1073/pnas.1420370112


Moffitt Cancer Center
1320)
1322)

MAtch:1322 / 1322 /1950-Moffitt Cancer Center


This Location ALREADY exists:Moffitt Cancer Center
Winship Cancer Institute
1320)
1322)

MAtch:1322 / 1322 /1950-Winship Cancer Institute


This Location ALREADY exists:Winship Cancer Institute
Northwestern Memorial Hospital
1320)
1322)

MAtch:1322 / 1322 /1950-Northwestern Memorial Hospital


This Location ALREADY exists:Northwestern Memorial Hospital
University of Chicago Medical Center
1320)
1322)

MAtch:1322 / 1322 /1950-University of Chicago Medical Center


This Location ALREADY exists:University of Chicago Medical Center
Dana Farber Cancer Institute
1320)
1322)

MAtch:1322 / 1322 /1950-Dana Farber Cancer Institute


This Location ALREADY exists:Dana Farber Cancer Institute
Oncology Hematology West, PC dba Nebraska Cancer Specialists
1320)
1322)

MAtch:1322 / 1322 /1950-Oncology Hematology West, PC dba Nebraska Cancer Specialists


This Location ALREADY exists:Oncology Hematology West, PC dba Nebraska Cancer Specialists
Albert Einstein Medical College
1320)
1322)

MAtch:1322 / 1322 /1950-Albert Einstein Medical College


This Location ALREADY exists:Albert Einstein Medical College
University of Rochester Medical Center
1320)
1322)

MAtch:1322 / 1322 /1950-University of Rochester Medical Center


This Location ALREADY exists:University of Rochester Medical Center
Novant Health Hematology - Forsyth
1320)
1322)

MAtch:1322 / 1322 /1950-Novant Health Hematology - Forsyth


This Location ALREADY exists:Novant Health Hematology – Forsyth
The Ohio State University Wexner Medical Center - James Cancer Hospital
1320)
1322)

MAtch:1322 / 1322 /1950-The Ohio State University Wexner Medical Center - James Cancer Hospital


This Location ALREADY exists:The Ohio State University Wexner Medical Center – James Cancer Hospital
The University of Texas MD Anderson Cancer Center
1320)
1322)

MAtch:1322 / 1322 /1950-The University of Texas MD Anderson Cancer Center


This Location ALREADY exists:The University of Texas MD Anderson Cancer Center
Vseobecna Fakultni nemocnice v Praze
1320)
1322)

MAtch:1322 / 1322 /1950-Vseobecna Fakultni nemocnice v Praze


This Location ALREADY exists:Vseobecna Fakultni nemocnice v Praze
Service d'hématologie clinique CHU de Nice
1320)
1322)

MAtch:1322 / 1322 /1950-Service d'hématologie clinique CHU de Nice


This Location ALREADY exists:Service d’hématologie clinique CHU de Nice
APHP - Sorbonne Universite
1320)
1322)

MAtch:1322 / 1322 /1950-APHP - Sorbonne Universite


This Location ALREADY exists:APHP – Sorbonne Universite
APHP - Hopital Saint Louis
1320)
1322)

MAtch:1322 / 1322 /1950-APHP - Hopital Saint Louis


This Location ALREADY exists:APHP – Hopital Saint Louis
Marien Hospital Dusseldorf; Klinik fur Onkologie und Hamatologie, Palliativmedizin
1320)
1322)

MAtch:1322 / 1322 /1950-Marien Hospital Dusseldorf; Klinik fur Onkologie und Hamatologie, Palliativmedizin


This Location ALREADY exists:Marien Hospital Dusseldorf; Klinik fur Onkologie und Hamatologie, Palliativmedizin
Universitatsklinikum Leipzig; Medizinische Klinik und Poliklinik I
1320)
1322)

MAtch:1322 / 1322 /1950-Universitatsklinikum Leipzig; Medizinische Klinik und Poliklinik I


This Location ALREADY exists:Universitatsklinikum Leipzig; Medizinische Klinik und Poliklinik I
Klinikum rechts der Isar der Technischen Universitat Munchen
1320)
1322)

MAtch:1322 / 1322 /1950-Klinikum rechts der Isar der Technischen Universitat Munchen


This Location ALREADY exists:Klinikum rechts der Isar der Technischen Universitat Munchen
Universitatsklinikum Munster
1320)
1322)

MAtch:1322 / 1322 /1950-Universitatsklinikum Munster


This Location ALREADY exists:Universitatsklinikum Munster
Soroka University MC
1320)
1322)

MAtch:1322 / 1322 /1950-Soroka University MC


This Location ALREADY exists:Soroka University MC
Edith Wolfson Medical Center
1320)
1322)

MAtch:1322 / 1322 /1950-Edith Wolfson Medical Center


This Location ALREADY exists:Edith Wolfson Medical Center
Hadassah University MC
1320)
1322)

MAtch:1322 / 1322 /1950-Hadassah University MC


This Location ALREADY exists:Hadassah University MC
Azienda Ospedaliera Santa Croce e Carle
1320)
1322)

MAtch:1322 / 1322 /1950-Azienda Ospedaliera Santa Croce e Carle


This Location ALREADY exists:Azienda Ospedaliera Santa Croce e Carle
Instituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
1320)
1322)

MAtch:1322 / 1322 /1950-Instituto Romagnolo per lo Studio dei Tumori "Dino Amadori"


This Location ALREADY exists:Instituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz
1320)
1322)

MAtch:1322 / 1322 /1950-Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz


This Location ALREADY exists:Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz
University Hospital in Krakow
1320)
1322)

MAtch:1322 / 1322 /1950-University Hospital in Krakow


This Location ALREADY exists:University Hospital in Krakow
Hospital de la Santa Creu I Sant Pau (Neuvo Hospital)
1320)
1322)

MAtch:1322 / 1322 /1950-Hospital de la Santa Creu I Sant Pau (Neuvo Hospital)


This Location ALREADY exists:Hospital de la Santa Creu I Sant Pau (Neuvo Hospital)
Hospital Universitaro del a Princesa
1320)
1322)

MAtch:1322 / 1322 /1950-Hospital Universitaro del a Princesa


This Location ALREADY exists:Hospital Universitaro del a Princesa
MD Anderson Cancer Center Madrid
1320)
1322)

MAtch:1322 / 1322 /1950-MD Anderson Cancer Center Madrid


This Location ALREADY exists:MD Anderson Cancer Center Madrid
Hospital Universitario Virgen del Rocio
1320)
1322)

MAtch:1322 / 1322 /1950-Hospital Universitario Virgen del Rocio


This Location ALREADY exists:Hospital Universitario Virgen del Rocio1